clindamycin plus benzoyl peroxide and adapalene

Details

Files
Generic Name:
clindamycin plus benzoyl peroxide and adapalene
Project Status:
Active
Therapeutic Area:
acne vulgaris
Manufacturer:
Bausch Health, Canada Inc.
Call for patient/clinician input open:
Brand Name:
Cabtreo
Project Line:
Reimbursement Review
Project Number:
SR0794-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input openJanuary 29, 2024
Call for patient/clinician input closedMarch 25, 2024
Clarification:

- Patient input submission received from Acne and Rosacea Society of Canada (ARSC) and Canadian Skin Patient Alliance (CSPA)

Submission receivedMarch 08, 2024
Submission acceptedMarch 26, 2024
Clarification:

- Submission was not accepted for review on 25 Mar 2024

Review initiatedMarch 27, 2024
Draft CADTH review report(s) provided to sponsor for commentJune 20, 2024
Deadline for sponsors commentsJuly 03, 2024
CADTH review report(s) and responses to comments provided to sponsorAugust 16, 2024
Expert committee meeting (initial)August 28, 2024
Draft recommendation issued to sponsorSeptember 11, 2024
Draft recommendation posted for stakeholder feedbackSeptember 19, 2024
End of feedback periodOctober 04, 2024